Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2016

Open Access 01-12-2016 | Review

Macrolides and associated antibiotics based on similar mechanism of action like lincosamides in malaria

Authors: Tiphaine Gaillard, Jérôme Dormoi, Marylin Madamet, Bruno Pradines

Published in: Malaria Journal | Issue 1/2016

Login to get access

Abstract

Malaria, a parasite vector-borne disease, is one of the biggest health threats in tropical regions, despite the availability of malaria chemoprophylaxis. The emergence and rapid extension of Plasmodium falciparum resistance to various anti-malarial drugs has gradually limited the potential malaria therapeutics available to clinicians. In this context, macrolides and associated antibiotics based on similar mechanism of action like lincosamides constitute an interesting alternative in the treatment of malaria. These molecules, whose action spectrum is similar to that of tetracyclines, are typically administered to children and pregnant women. Recent studies have examined the effects of azithromycin and the lincosamide clindamycin, on isolates from different continents. Azithromycin and clindamycin are effective and well tolerated in the treatment of uncomplicated malaria in combination with quinine. This literature review assesses the roles of macrolides and lincosamides in the prophylaxis and treatment of malaria.
Literature
1.
WHO. World malaria report. Geneva: World Health Organization; 2014.
2.
3.
Dunne MW, Singh N, Shukla M, Valecha N, Bhattacharyya PC, Dev V, et al. A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Infect Dis. 2005;191:1582–8.CrossRefPubMed
4.
Chico RM, Pittrof R, Greenwood B, Chandramohan D. Azithromycin–chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malar J. 2008;7:255.PubMedCentralCrossRefPubMed
5.
McGready R, Cho T, Samuel S, Villegas L, Brockman A, van Vugt M, et al. Randomized comparison of quinine–clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg. 2001;95:651–6.CrossRefPubMed
6.
Borrmann S, Issifou S, Esser G, Adegnika AA, Ramharter M, Matsiegui P-B, et al. Fosmidomycin–clindamycin for the treatment of Plasmodium falciparum malaria. J Infect Dis. 2004;190:1534–40.CrossRefPubMed
7.
Ramharter M, Oyakhirome S, Klein Klouwenberg P, Adégnika AA, Agnandji ST, Missinou MA, et al. Artesunate–clindamycin versus quinine–clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial. Clin Infect Dis. 2005;40:1777–84.CrossRefPubMed
8.
Kalilani L, Mofolo I, Chaponda M, Rogerson SJ, Alker AP, Kwiek JJ, et al. A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine–pyrimethamine as treatment for malaria in pregnant women. PLoS One. 2007;2:1166.CrossRef
9.
Sykes A, Hendriksen I, Mtove G, Mandea V, Mrema H, Rutta B, et al. Azithromycin plus artesunate versus artemether–lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin Infect Dis. 2009;49:1195–201.CrossRefPubMed
10.
Laufer MK, Thesing PC, Dzinjalamala FK, Nyirenda OM, Masonga R, Laurens MB, et al. A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone–proguanil to treat malaria. PLoS One. 2012;7:42284.CrossRef
11.
Sagara I, Oduro AR, Mulenga M, Dieng Y, Ogutu B, Tiono AB, et al. Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults. Malar J. 2014;13:458.PubMedCentralCrossRefPubMed
12.
Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother. 1993;31(Suppl C):1–9.CrossRefPubMed
13.
Carbon C. Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis. 1998;27:28–32.CrossRefPubMed
14.
Goodman CD, Useglio M, Peirú S, Labadie GR, McFadden GI, Rodríguez E, et al. Chemobiosynthesis of new antimalarial macrolides. Antimicrob Agents Chemother. 2013;57:907–13.PubMedCentralCrossRefPubMed
15.
Ballow CH, Amsden GW. Azithromycin: the first azalide antibiotic. Ann Pharmacother. 1992;26:1253–61.PubMed
16.
Sidhu ABS, Sun Q, Nkrumah LJ, Dunne MW, Sacchettini JC, Fidock DA. In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J Biol Chem. 2007;282:2494–504.CrossRefPubMed
17.
Gingras BA, Jensen JB. Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Am J Trop Med Hyg. 1992;47:378–82.PubMed
18.
Parnham MJ. Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 2014;143:225–45.CrossRefPubMed
19.
Nilsen OG. Comparative pharmacokinetics of macrolides. J Antimicrob Chemother. 1987;20(Suppl B):81–8.CrossRefPubMed
20.
Kremsner PG, Zotter GM, Feldmeier H, Graninger W, Rocha RM, Wiedermann G. A comparative trial of three regimens for treating uncomplicated falciparum malaria in Acre, Brazil. J Infect Dis. 1988;158:1368–71.CrossRefPubMed
21.
Touze JE, Heno P, Fourcade L, Deharo JC, Thomas G, Bohan S, et al. The effects of antimalarial drugs on ventricular repolarization. Am J Trop Med Hyg. 2002;67:54–60.PubMed
22.
Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M, Suter W. Inhibition of hERG K + currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol. 2004;484:41–8.CrossRefPubMed
23.
Fossa AA, Wisialowski T, Duncan JN, Deng S, Dunne M. Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig. Am J Trop Med Hyg. 2007;77:929–38.PubMed
24.
25.
Fleige T, Soldati-Favre D. Targeting the transcriptional and translational machinery of the endosymbiotic organelle in apicomplexans. Curr Drug Targets. 2008;9:948–56.CrossRefPubMed
26.
Yeh E, DeRisi JL. Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum. PLoS Biol. 2011;9:e1001138.PubMedCentralCrossRefPubMed
27.
Goodman CD, Su V, McFadden GI. The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol Biochem Parasitol. 2007;152:181–91.CrossRefPubMed
28.
Pradines B, Rogier C, Fusai T, Mosnier J, Daries W, Barret E, et al. In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron. Antimicrob Agents Chemother. 2001;45:1746–50.PubMedCentralCrossRefPubMed
29.
Fichera ME, Bhopale MK, Roos DS. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother. 1995;39:1530–7.PubMedCentralCrossRefPubMed
30.
Hutinec A, Rupčić R, Ziher D, Smith KS, Milhous W, Ellis W, Ohrt C, et al. An automated, polymer-assisted strategy for the preparation of urea and thiourea derivatives of 15-membered azalides as potential antimalarial chemotherapeutics. Bioorg Med Chem. 2011;19:1692–701.CrossRefPubMed
31.
Perić M, Fajdetić A, Rupčić R, Alihodžić S, Ziher D, Bukvić Krajačić M, et al. Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. J Med Chem. 2012;55:1389–401.CrossRefPubMed
32.
Pešić D, Starčević K, Toplak A, Herreros E, Vidal J, Almela MJ, et al. Design, synthesis, and in vitro activity of novel 2′-O-substituted 15-membered azalides. J Med Chem. 2012;55:3216–27.CrossRefPubMed
33.
Camps M, Arrizabalaga G, Boothroyd J. An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii. Mol Microbiol. 2002;43:1309–18.CrossRefPubMed
34.
Fichera ME, Roos DS. A plastid organelle as a drug target in apicomplexan parasites. Nature. 1997;390:407–9.CrossRefPubMed
35.
Seaberg LS, Parquette AR, Gluzman IY, Phillips GW, Brodasky TF, Krogstad DJ. Clindamycin activity against chloroquine-resistant Plasmodium falciparum. J Infect Dis. 1984;150:904–11.CrossRefPubMed
36.
Poehlsgaard J, Douthwaite S. The bacterial ribosome as a target for antibiotics. Nat Rev Microbiol. 2005;3:870–81.CrossRefPubMed
37.
Gingras BA, Jensen JB. Antimalarial activity of azithromycin and erythromycin against Plasmodium berghei. Am J Trop Med Hyg. 1993;49:101–5.PubMed
38.
Gao D, Amza A, Nassirou B, Kadri B, Sippl-Swezey N, Liu F, et al. Optimal seasonal timing of oral azithromycin for malaria. Am J Trop Med Hyg. 2014;91:936–42.PubMedCentralCrossRefPubMed
39.
Van Eijk AM, Terlouw DJ: Azithromycin for treating uncomplicated malaria. Cochrane Database Syst Rev. 2011;CD006688.
40.
Ohrt C, Willingmyre GD, Lee P, Knirsch C, Milhous W. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 2002;46:2518–24.PubMedCentralCrossRefPubMed
41.
Noedl H, Krudsood S, Chalermratana K, Silachamroon U, Leowattana W, Tangpukdee N, et al. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis. 2006;43:1264–71.CrossRefPubMed
42.
Nakornchai S, Konthiang P. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006;100:185–91.CrossRefPubMed
43.
Thriemer K, Starzengruber P, Khan WA, Haque R, Marma ASP, Ley B, et al. Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial. J Infect Dis. 2010;202:392–8.CrossRefPubMed
44.
Miller RS, Wongsrichanalai C, Buathong N, McDaniel P, Walsh DS, Knirsch C, et al. Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin–quinine combinations: a randomized, dose-ranging study. Am J Trop Med Hyg. 2006;74:401–6.PubMed
45.
Clark RL, White TEK, A Clode S, Gaunt I, Winstanley P, Ward SA. Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. Birth Defects Res B Dev Reprod Toxicol. 2004;71:380–94.CrossRefPubMed
46.
Hastings IM, Ward SA. Coartem (artemether–lumefantrine) in Africa: the beginning of the end? J Infect Dis. 2005;192:1303–4.CrossRefPubMed
47.
Dhawan VK, Thadepalli H. Clindamycin: a review of fifteen years of experience. Rev Infect Dis. 1982;4:1133–53.CrossRefPubMed
48.
49.
50.
Clyde DF, Gilman RH, McCarthy VC. Antimalarial effects of clindamycin in man. Am J Trop Med Hyg. 1975;24:369–70.PubMed
51.
Kremsner PG, Zotter GM, Feldmeier H, Graninger W, Westerman RL, Rocha RM. Clindamycin treatment of falciparum malaria in Brazil. J Antimicrob Chemother. 1989;23:275–81.CrossRefPubMed
52.
Kremsner PG, Winkler S, Brandts C, Neifer S, Bienzle U, Graninger W. Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J Infect Dis. 1994;169:467–70.CrossRefPubMed
53.
Miller LH, Glew RH, Wyler DJ, Howard WA, Collins WE, Contacos PG, et al. Evaluation of clindamycin in combination with quinine against multidrug-resistant strains of Plasmodium falciparum. Am J Trop Med Hyg. 1974;23:565–9.PubMed
54.
Metzger W, Mordmüller B, Graninger W, Bienzle U, Kremsner PG. High efficacy of short-term quinine–antibiotic combinations for treating adult malaria patients in an area in which malaria is hyperendemic. Antimicrob Agents Chemother. 1995;39:245–6.PubMedCentralCrossRefPubMed
55.
White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997;41:1413–22.PubMedCentralPubMed
56.
Kremsner PG, Winkler S, Brandts C, Graninger W, Bienzle U. Curing of chloroquine-resistant malaria with clindamycin. Am J Trop Med Hyg. 1993;49:650–4.PubMed
57.
Vaillant M, Millet P, Luty A, Tshopamba P, Lekoulou F, Mayombo J, et al. Therapeutic efficacy of clindamycin in combination with quinine for treating uncomplicated malaria in a village dispensary in Gabon. Trop Med Int Health. 1997;2:917–9.CrossRefPubMed
58.
Missinou MA, Borrmann S, Schindler A, Issifou S, Adegnika AA, Matsiegui P-B, et al. Fosmidomycin for malaria. Lancet. 2002;360:1941–2.CrossRefPubMed
59.
World Health Organization. Guidelines for the treatment of malaria. 2nd ed. 2010.
60.
Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet. 2000;356:297–302.CrossRefPubMed
61.
Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002;2:209–18.CrossRefPubMed
62.
White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia. 1999;41:301–8.PubMed
63.
Alecrim M das GC, Carvalho LM, Andrade SD, Arcanjo ARL, Alexandre MA, Alecrim WD. Treatment of children with malaria Plasmodium falciparum with derivatives artemisinin. Rev Soc Bras Med Trop. 2003;36:223–6.CrossRefPubMed
64.
Vivas L, Rattray L, Stewart LB, Robinson BL, Fugmann B, Haynes RK, et al. Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. J Antimicrob Chemother. 2007;59:658–65.CrossRefPubMed
65.
Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002;34:482–92.CrossRefPubMed
66.
Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother. 1999;43:2823–30.PubMedCentralPubMed
67.
68.
69.
Zhong P, Shortridge VD. The role of efflux in macrolide resistance. Drug Resist Updat. 2000;3:325–9.CrossRefPubMed
70.
Hagman KE, Lucas CE, Balthazar JT, Snyder L, Nilles M, Judd RC, et al. The MtrD protein of Neisseria gonorrhoeae is a member of the resistance/nodulation/division protein family constituting part of an efflux system. Microbiology. 1997;143:2117–25.CrossRefPubMed
71.
Schoner B, Geistlich M, Rosteck P, Rao RN, Seno E, Reynolds P, et al. Sequence similarity between macrolide-resistance determinants and ATP-binding transport proteins. Gene. 1992;115:93–6.CrossRefPubMed
72.
Matsuoka M, Endou K, Kobayashi H, Inoue M, Nakajima Y. A plasmid that encodes three genes for resistance to macrolide antibiotics in Staphylococcus aureus. FEMS Microbiol Lett. 1998;167:221–7.CrossRefPubMed
73.
Matsuoka M, Sasaki T. Inactivation of macrolides by producers and pathogens. Curr Drug Targets Infect Disord. 2004;4:217–40.CrossRefPubMed
74.
Lüthje P, von Köckritz-Blickwede M, Schwarz S. Identification and characterization of nine novel types of small staphylococcal plasmids carrying the lincosamide nucleotidyltransferase gene lnu(A). J Antimicrob Chemother. 2007;59:600–6.CrossRefPubMed
75.
Jacobs RL, Koontz LC. Plasmodium berghei: development of resistance to clindamycin and minocycline in mice. Exp Parasitol. 1976;40:116–23.CrossRefPubMed
76.
Koontz LC, Jacobs RL, Lummis WL, Miller LH. Plasmodium berghei: uptake of clindamycin and its metabolites by mouse erythrocytes with clindamycin-sensitive and clindamycin-resistant parasites. Exp Parasitol. 1979;48:206–12.CrossRefPubMed
77.
Gardner MJ, Feagin JE, Moore DJ, Rangachari K, Williamson DH, Wilson RJ. Sequence and organization of large subunit rRNA genes from the extrachromosomal 35 kb circular DNA of the malaria parasite Plasmodium falciparum. Nucleic Acids Res. 1993;21:1067–71.PubMedCentralCrossRefPubMed
78.
Na-Bangchang K, Kanda T, Tipawangso P, Thanavibul A, Suprakob K, Ibrahim M, et al. Activity of artemether–azithromycin versus artemether–doxycycline in the treatment of multiple drug resistant falciparum malaria. Southeast Asian J Trop Med Public Health. 1996;27:522–5.PubMed
79.
80.
Alecrim M das G, Dourado H, Alecrim W, Albuquerque BC, Wanssa E, Wanssa Mdo C. Treatment of malaria (P. falciparum) with clindamycin. Rev Inst Med Trop Sao Paulo. 1981;23:86–91.PubMed
81.
Alecrim WD, Albuquerque BC, Alecrim MG, Dourado H. Treatment of malaria (P. falciparum) with clindamycin. II—dosage schedule for 5 days. Rev Inst Med Trop Sao Paulo. 1982;24:40–3.PubMed
82.
Rivera DG, Cabrera BD, Lara NT. Treatment of falciparum malaria with clindamycin. Rev Inst Med Trop Sao Paulo. 1982;24:70–5.PubMed
83.
Cabrera BD, Rivera DG, Lara NT. Study on clindamycin in the treatment of falciparum malaria. Rev Inst Med Trop Sao Paulo. 1982;24:62–9.PubMed
84.
Restrepo A, Restrepo M, Baena C, Mejia B, Sossa P, Salazar M. Tratamiento con clindamicina de la malaria por falciparum resistente. Acta Med Col. 1984;9:15–21.
85.
El Wakeel ES, Homeida MM, Ali HM, Geary TG, Jensen JB. Clindamycin for the treatment of falciparum malaria in Sudan. Am J Trop Med Hyg. 1985;34:1065–8.PubMed
86.
Meira DA, Pereira PC, Marcondes-Machado J, Mendes RP, Barraviera B, Pirola JA, et al. Malaria in Humaita County, State of Amazonas, Brazil. XIX—Evaluation of clindamycin for the treatment of patients with Plasmodium falciparum infection. Rev Soc Bras Med Trop. 1988;21:123–9.CrossRefPubMed
87.
Salazar NP, Saniel MC, Estoque MH, Talao FA, Bustos DG, Palogan LP, et al. Oral clindamycin in the treatment of acute uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health. 1990;21:397–403.PubMed
88.
Oemijati S, Pribadi W, Wartati K, Arbani P, Suprijanto S, Rasisi R, Zambrano D. Treatment of chloroquine-resistant Plasmodium falciparum infections with clindamycin hydrochloride in Dili, East Timor. Indonesia. Curr Ther Res Clin Exp. 1994;55:468–79.CrossRef
89.
Metzger W, Mordmüller B, Graninger W, Bienzle U, Kremsner PG. Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. J Antimicrob Chemother. 1995;36:723–8.CrossRefPubMed
90.
Kremsner PG, Radloff P, Metzger W, Wildling E, Mordmüller B, Philipps J, et al. Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob Agents Chemother. 1995;39:1603–5.PubMedCentralCrossRefPubMed
91.
Parola P, Ranque S, Badiaga S, Niang M, Blin O, Charbit JJ, et al. Controlled trial of 3-day quinine–clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother. 2001;45:932–5.PubMedCentralCrossRefPubMed
92.
Pukrittayakamee S, Chantra A, Vanijanonta S, Clemens R, Looareesuwan S, White NJ. Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob Agents Chemother. 2000;44:2395–8.PubMedCentralCrossRefPubMed
Metadata
Title
Macrolides and associated antibiotics based on similar mechanism of action like lincosamides in malaria
Authors
Tiphaine Gaillard
Jérôme Dormoi
Marylin Madamet
Bruno Pradines
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2016
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-016-1114-z

Other articles of this Issue 1/2016

Malaria Journal 1/2016 Go to the issue

Research

Quantifying the removal of red blood cells in Macaca mulatta during a Plasmodium coatneyi infection

Research

Seeking treatment for uncomplicated malaria: experiences from the Kintampo districts of Ghana

Research

A significant association between deltamethrin resistance, Plasmodium falciparum infection and the Vgsc-1014S resistance mutation in Anopheles gambiae highlights the epidemiological importance of resistance markers

Research

The risk of imported malaria in security forces personnel returning from overseas missions in the context of prevention of re-introduction of malaria to Sri Lanka

Research

Sickle haemoglobin, haemoglobin C and malaria mortality feedbacks

Methodology

A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits